Study to Evaluate the Treatment Effect of PT003 on Cardiac Stroke Volume in Subjects With Moderate to Severe COPD

Not yet recruiting

Phase 3 Results N/A

Summary of Purpose

This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on cardiac stroke volume following chronic-dosing (7 days) in subjects with moderate to severe COPD.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 February 2016.

1 Feb 2016 28 Jan 2016 1 Jan 2017 1 May 2017 1 Feb 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Crossover Assignment


  • Catherine Pelc